BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21152880)

  • 1. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
    De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
    Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
    de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
    Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
    Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
    PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
    Duenas-Gonzalez A; Candelaria M; Perez-Plascencia C; Perez-Cardenas E; de la Cruz-Hernandez E; Herrera LA
    Cancer Treat Rev; 2008 May; 34(3):206-22. PubMed ID: 18226465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
    Song Y; Zhang C
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
    Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
    Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes.
    Milutinovic S; D'Alessio AC; Detich N; Szyf M
    Carcinogenesis; 2007 Mar; 28(3):560-71. PubMed ID: 17012225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
    Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
    PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to pathogenic gene function discovery with human squamous cell cervical carcinoma by gene ontology.
    Seo MJ; Bae SM; Kim YW; Kim YW; Hur SY; Ro DY; Lee JM; Namkoong SE; Kim CK; Ahn WS
    Gynecol Oncol; 2005 Mar; 96(3):621-9. PubMed ID: 15721403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.
    Zambrano P; Segura-Pacheco B; Perez-Cardenas E; Cetina L; Revilla-Vazquez A; Taja-Chayeb L; Chavez-Blanco A; Angeles E; Cabrera G; Sandoval K; Trejo-Becerril C; Chanona-Vilchis J; Duenas-González A
    BMC Cancer; 2005 Apr; 5():44. PubMed ID: 15862127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
    Soto A; DelRaso NJ; Schlager JJ; Chan VT
    Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
    Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
    Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    Li LC; Carroll PR; Dahiya R
    J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
    Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
    Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.